The results showed that inhibitors of ferroptosis and apoptosis compromised the suppressive effect of decitabine on GPX4 in low-risk MDS, whereas inhibitors of ferroptosis and necrosis antagonized decitabine’s suppression on GPX4 in high-risk MDS. This evidence concerns the gene GPX4 and myelodysplastic syndrome.